Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Analysis of: New Inhalation Device With Aclidinium Bromide May Offer Advantages To COPD Patients (www.medicalnewstoday.com)
the LAMA class currently only has 1 product: tiotropium the LAMA class is indicated for early stages of COPD (GOLD stage II and beyond) many patients are on LAMAs and LABAs, but no company has the 2 classes in 1 inhaler.  Almirall has a Phase II study of LAMAs and LABA (formoterol) together Advanced...
Analysis of: F.D.A. Criticizes Avastin Use for Breast Cancer (www.nytimes.com)
While the drug Avastin improves time to disease progression, it does not prolong survival and is associated, in the FDA's view, undue toxicity.
Analysis of: AstraZeneca Completes Enrollment In First Phase III Study Of The Investigational Drug Vandetanib (ZACTIMA(R)) In Non-Small Cell Lung Cancer (www.pipelinereview.com)
This trial as well as three others: -- ZODIAC (vandetanib + docetaxel versus docetaxel alone) -- ZEAL (vandetanib + pemetrexed versus placebo+ pemetrexed); and, -- ZEPHYR (vandetanib + best supportive care (BSC) versus placebo +  BSC).   are being carried out to prove efficacy with &...
Analysis of: New Data Highlight That Treatment With Erbitux Allows More Resections of Preteated Patients With Metastatic Colorectal Cancer (www.pipelinereview.com)
Just like Vascular Endothelial Factor Receptor Inhibitor (VEGF) Avastin Genentech, Erbitux a Endothelial Growth Factor Receptor Inhibitor (EGFR), can make previously unresectable metastatic colon cancer resectable.
Analysis of: Buffalo News Announces Start of Clinical Trial for KX2-391 (www.pipelinereview.com)
Phase I trials rtarting at MD Anderson and Roswell Park Cancer Centers. A kinase inhibitor!
Analysis of: Eltrombopag for Thrombocytopenia in Patients with Cirrhosis Associated with Hepatitis C (content.nejm.org)
An oral agent that will increase platelet counts by increasing release from the bone marrow!! Way cool!!!
Analysis of: Wyeth Cancer Drug Torisel Gets European Commission Approval (www.therapeuticsdaily.com)
Torisel has now been approved in Europe for therapy of advanced kidney cancer (RCC)
Analysis of: Tasigna Gains European Approval for Patients with a Life-Threatening Form of Leukemia Who Are Resistant or Intolerant to Existing Therapies (www.therapeuticsdaily.com)
Approved in the US and now Europe for Gleevec (Novartis) intolerant or resistant Chronic Myelogenous Leukemia (CML) patients.
Analysis of: Vaxon Biotech Obtains Orphan Status for Lung Cancer Vaccine (www.therapeuticsdaily.com)
This product of Vaxon Biotech is just being studied in non small cell lung cancer (NSCLCA)
Analysis of: Pharmexa provides update on the HeptoVax trial of GV1001 in liver cancer (www.pipelinereview.com)
Pharmexa's HeptoVax trial of GV1001 is well underway to determine if it has efficacy in hepatocellular carcinoma (HCC.)

Previous Page : 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 Next221 to 230 of 457

Analytics


Generated at 2009-01-07T19:00:58.307